Q2 2024 EPS Estimates for argenx SE (NASDAQ:ARGX) Lifted by Analyst

argenx SE (NASDAQ:ARGX) – Research analysts at William Blair lifted their Q2 2024 earnings estimates for shares of argenx in a research note issued to investors on Thursday, April 18th. William Blair analyst M. Minter now expects that the company will post earnings per share of ($0.83) for the quarter, up from their prior forecast of ($1.03). The consensus estimate for argenx’s current full-year earnings is ($2.10) per share. William Blair also issued estimates for argenx’s Q3 2024 earnings at ($0.63) EPS, Q4 2024 earnings at ($0.62) EPS, Q1 2025 earnings at $0.16 EPS, Q2 2025 earnings at $0.51 EPS, Q3 2025 earnings at $0.77 EPS and Q4 2025 earnings at $1.35 EPS.

Several other research firms have also commented on ARGX. Wedbush restated an “outperform” rating and issued a $521.00 price target on shares of argenx in a report on Thursday, April 18th. Wolfe Research began coverage on shares of argenx in a research note on Thursday, February 15th. They set a “peer perform” rating for the company. Truist Financial boosted their price objective on shares of argenx from $370.00 to $440.00 and gave the stock a “buy” rating in a research note on Tuesday, March 5th. Scotiabank boosted their price objective on shares of argenx from $402.00 to $408.00 and gave the stock a “sector perform” rating in a research note on Tuesday, March 26th. Finally, Piper Sandler boosted their price objective on shares of argenx from $518.00 to $522.00 and gave the stock an “overweight” rating in a research note on Friday, January 26th. One analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, argenx presently has a consensus rating of “Moderate Buy” and an average target price of $528.16.

argenx Stock Performance

NASDAQ:ARGX opened at $375.08 on Monday. argenx has a one year low of $327.73 and a one year high of $550.76. The firm has a market cap of $22.29 billion, a P/E ratio of -72.97 and a beta of 0.65. The firm has a 50-day simple moving average of $386.95 and a 200-day simple moving average of $419.33.

argenx (NASDAQ:ARGX) last posted its quarterly earnings results on Thursday, February 29th. The company reported ($1.68) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.45). argenx had a negative net margin of 23.26% and a negative return on equity of 16.97%. The business had revenue of $417.84 million during the quarter, compared to the consensus estimate of $378.60 million. During the same quarter in the prior year, the firm posted ($0.70) EPS.

Institutional Trading of argenx

Large investors have recently made changes to their positions in the business. Nkcfo LLC boosted its holdings in argenx by 22.1% during the third quarter. Nkcfo LLC now owns 116 shares of the company’s stock worth $57,000 after buying an additional 21 shares in the last quarter. Genus Capital Management Inc. boosted its holdings in argenx by 1.6% during the third quarter. Genus Capital Management Inc. now owns 1,605 shares of the company’s stock worth $789,000 after buying an additional 25 shares in the last quarter. Wahed Invest LLC boosted its holdings in argenx by 9.6% during the fourth quarter. Wahed Invest LLC now owns 457 shares of the company’s stock worth $174,000 after buying an additional 40 shares in the last quarter. Daiwa Securities Group Inc. boosted its holdings in argenx by 2.8% during the fourth quarter. Daiwa Securities Group Inc. now owns 1,530 shares of the company’s stock worth $582,000 after buying an additional 41 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC boosted its holdings in argenx by 3.1% during the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 1,428 shares of the company’s stock worth $543,000 after buying an additional 43 shares in the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.